[Bone quality and raloxifene].

Bone turnover affects fracture risk. Degrees of fracture risk reduction by antiresorptive agents are larger than those expected from the rates of BMD increase. Actually, fracture risk reduction by raloxifene is largely dependent on the effects of bone turnover regulation. Raloxifene stabilizes the trabecular structure, maintains the activities of micro-injury repair and healing of fracture, and increases the mean values of the degrees of tissue mineralization and the distribution of their ranges. The relationship between the fracture risk reduction and the changes in these parameters of bone quality is not clear. Further information is necessary based on the data of clinical practice.